FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3016940624> ?p ?o ?g. }

• W3016940624 endingPage "121" @default.
• W3016940624 startingPage "112" @default.
• W3016940624 abstract "Introduction High incidence of bleeding events remains a key risk for patients taking anticoagulants, especially those in need of long-term combination therapy with antiplatelet agents. As a consequence, patients may not receive clinically indicated combination antithrombotic therapy. Here, we report on VE-1902, a member of a novel class of precision oral anticoagulants (PROACs) that combines effective anticoagulation with reduced bleeding in preclinical testing. Methods and results Acting through covalent, reversible active-site modification of thrombin similar to a previously described molecule [ [1] Sivaraja M. Pozzi N. Rienzo M. et al. Reversible covalent direct thrombin inhibitors. PLoS ONE. 2018; 13e0201377 Crossref PubMed Scopus (12) Google Scholar ], VE-1902 shows potency and selectivity for thrombin inhibition in human plasma comparable to clinically relevant direct thrombin inhibitors (DTI) such as argatroban and dabigatran (thrombin generation assay ETP EC50 = 1.3 μM compared to 0.36 μM and 0.31 μM for argatroban and dabigatran; >100-fold selectivity against related serine proteases). Unlike the current anticoagulants, VE-1902 does not significantly inhibit thrombin-mediated platelet activation in in vivo models of thrombosis. In the thrombin generation assay, the compound inhibits thrombin formation without significantly delaying the initiation phase of the clotting cascade. These features are possibly responsible for the observed reduced bleeding in tail bleeding and saphenous vein bleeding models. Consistent with this novel pharmacological profile, VE-1902 shows efficacious anticoagulation in several fibrin-driven animal models of thrombosis (arteriovenous shunt, venous stasis thrombosis, and thrombin-induced thromboembolism models), whereas it does not significantly prevent arterial occlusion in the platelet dependent FeCl3 model. Conclusions By leaving platelet activation following vascular injury mostly unaffected, VE-1902, and the PROACs more generally, represent a new generation of precision anticoagulants with reduced bleeding risk." @default.
• W3016940624 created "2020-04-24" @default.
• W3016940624 creator A5000652623 @default.
• W3016940624 creator A5003479195 @default.
• W3016940624 creator A5003841060 @default.
• W3016940624 creator A5004303644 @default.
• W3016940624 creator A5007026783 @default.
• W3016940624 creator A5007864971 @default.
• W3016940624 creator A5009960575 @default.
• W3016940624 creator A5010686969 @default.
• W3016940624 creator A5013436081 @default.
• W3016940624 creator A5016111118 @default.
• W3016940624 creator A5029693654 @default.
• W3016940624 creator A5030133341 @default.
• W3016940624 creator A5035157614 @default.
• W3016940624 creator A5042548034 @default.
• W3016940624 creator A5046701540 @default.
• W3016940624 creator A5053536324 @default.
• W3016940624 creator A5059209820 @default.
• W3016940624 creator A5061604812 @default.
• W3016940624 creator A5064149028 @default.
• W3016940624 creator A5068718934 @default.
• W3016940624 creator A5069084946 @default.
• W3016940624 creator A5082749266 @default.
• W3016940624 creator A5087503835 @default.
• W3016940624 date "2020-06-01" @default.
• W3016940624 modified "2023-09-29" @default.
• W3016940624 title "VE-1902—A direct thrombin inhibitor with reversible covalent mechanism of action shows efficacy with reduced bleeding in rodent models of thrombosis" @default.
• W3016940624 cites W1488297787 @default.
• W3016940624 cites W1515982653 @default.
• W3016940624 cites W1518333457 @default.
• W3016940624 cites W1580721419 @default.
• W3016940624 cites W1965317284 @default.
• W3016940624 cites W1970676078 @default.
• W3016940624 cites W1973274829 @default.
• W3016940624 cites W1979083993 @default.
• W3016940624 cites W1991655882 @default.
• W3016940624 cites W2014933829 @default.
• W3016940624 cites W2029903013 @default.
• W3016940624 cites W2031424136 @default.
• W3016940624 cites W2033577946 @default.
• W3016940624 cites W2034863939 @default.
• W3016940624 cites W2042478080 @default.
• W3016940624 cites W2064826963 @default.
• W3016940624 cites W2072461619 @default.
• W3016940624 cites W2089923109 @default.
• W3016940624 cites W2090120321 @default.
• W3016940624 cites W2100209149 @default.
• W3016940624 cites W2105317668 @default.
• W3016940624 cites W2108064339 @default.
• W3016940624 cites W2108659563 @default.
• W3016940624 cites W2108830010 @default.
• W3016940624 cites W2113089341 @default.
• W3016940624 cites W2117677020 @default.
• W3016940624 cites W2132979663 @default.
• W3016940624 cites W2134478125 @default.
• W3016940624 cites W2147076794 @default.
• W3016940624 cites W2158732221 @default.
• W3016940624 cites W2159370853 @default.
• W3016940624 cites W2160008932 @default.
• W3016940624 cites W2164564948 @default.
• W3016940624 cites W2170251955 @default.
• W3016940624 cites W2282129983 @default.
• W3016940624 cites W2293541891 @default.
• W3016940624 cites W2331609248 @default.
• W3016940624 cites W2339941938 @default.
• W3016940624 cites W2408475377 @default.
• W3016940624 cites W2427094903 @default.
• W3016940624 cites W2433067092 @default.
• W3016940624 cites W2556417520 @default.
• W3016940624 cites W2580792129 @default.
• W3016940624 cites W2749380187 @default.
• W3016940624 cites W2749929702 @default.
• W3016940624 cites W2755375976 @default.
• W3016940624 cites W2775903766 @default.
• W3016940624 cites W2799451270 @default.
• W3016940624 cites W2923122590 @default.
• W3016940624 cites W2926995464 @default.
• W3016940624 cites W4241450225 @default.
• W3016940624 cites W4244622180 @default.
• W3016940624 cites W93161560 @default.
• W3016940624 doi "https://doi.org/10.1016/j.thromres.2020.04.020" @default.
• W3016940624 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7936662" @default.
• W3016940624 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32339947" @default.
• W3016940624 hasPublicationYear "2020" @default.
• W3016940624 type Work @default.
• W3016940624 sameAs 3016940624 @default.
• W3016940624 citedByCount "8" @default.
• W3016940624 countsByYear W30169406242021 @default.
• W3016940624 countsByYear W30169406242022 @default.
• W3016940624 countsByYear W30169406242023 @default.
• W3016940624 crossrefType "journal-article" @default.
• W3016940624 hasAuthorship W3016940624A5000652623 @default.
• W3016940624 hasAuthorship W3016940624A5003479195 @default.
• W3016940624 hasAuthorship W3016940624A5003841060 @default.
• W3016940624 hasAuthorship W3016940624A5004303644 @default.
• W3016940624 hasAuthorship W3016940624A5007026783 @default.
• W3016940624 hasAuthorship W3016940624A5007864971 @default.

• next